This should be considered if ACE2 blockade is to be developed for COVID-19 treatment, although pharmacological inhibition of ACE2 in such a setting would be expected to be short term and elevations in blood pressure could be managed with antihypertensives. Here, ACE2 is linked to COVID-19.